Genetic epidemiology of breast and ovarian cancers

Epidemiologic Reviews

Volumn 19, Issue 1, 1997, Pages 69-79

  Newman, Beth ^a   Millikan, Robert C ^a   King, Mary Claire ^b  

^a IL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FEMALE; GENE LOCUS; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; INHERITANCE; MEDICAL ETHICS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH; REVIEW; SEGREGATION ANALYSIS; STATISTICAL ANALYSIS;

EID: 0030656606     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017948     Document Type: Review

References (128)

1. Broca P. Traites des tumeurs. Vol 1: Des tumeurs nen general. Paris, France: P Asselin, 1866.
2. Lane-Claypon JE. A further report on cancer of the breasts, with special reference to its associated antecedent conditions. Report on Public Health and Medical Subjects, no. 32. London, England: Ministry of Health, 1926.
3. Kelsey JL. A review of the epidemiology of human breast cancer. Epidemiol Rev 1979;1:74-109.
4. Kelsey JL, Gammon MD. Epidemiology of breast cancer. Epidemiol Rev 1990;12:228-40.
5. Eby N, Chang-Claude J, Bishop DT. Familial risk and genetic susceptibility for breast cancer. Cancer Causes Control 1994;5:458-70.
6. Rosenblatt KA, Thomas DB, McTiernan A, et al. Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst 1991;83:849-54.
7. Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer 1993;71(2 suppl):566-72.
8. Floderus B, Barlow L, Mack TM. Recall bias in subjective reports of familial cancer. Epidemiology 1990;1:318-21.
9. Love RR, Evans AM, Josten DM. The accuracy of patient reports of a family history of cancer. J Chronic Dis 1985;38: 289-93.
10. Khoury MJ, Flanders WD. Bias in using family history as a risk factor in case-control studies of disease. Epidemiology 1995;6:511-19.
11. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk: the Utah Population Database. JAMA 1993;270:1563-8.
12. Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer: prospective data from the Nurses' Health Study. JAMA 1993;270:338-43.
13. Tulinius H, Sigvaldason H, Olafsdottir G, et al. Epidemiology of breast cancer in families in Iceland. J Med Genet 1992;29:158-64.
14. Koch M, Gaedke H, Jenkins H. Family history of ovarian cancer patients: a case-control study. Int J Epidemiol 1989; 18:782-5.
15. Ottman R, Pike MC, King MC, et al. Familial breast cancer in a population-based series. Am J Epidemiol 1986;123: 15-21.
16. Schwartz AG, King MC, Belle SH, et al. Risk of breast cancer to relatives of young breast cancer patients. J Natl Cancer Inst 1985;75:665-8.
17. Amos CI, Shaw GL, Tucker MA, et al. Age at onset for familial epithelial ovarian cancer. JAMA 1992;268:1896-9.
18. Khoury MJ, Beaty TH, Liang KY. Can familial aggregation of disease be explained by familial aggregation of environmental risk factors? Am J Epidemiol 1988;127:674-83.
19. Hopper JL, Carlin JB. Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am J Epidemiol 1992;136: 1138-47.
20. Peto J. Genetic predisposition to cancer. In: Cairns J, Lyon JL, Skolnick M, eds. Cancer incidence in defined populations. Banbury report no. 4. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1980:203-13.
21. Weiss KM, Chakraborty R, Majumder PP, et al. Problems in the assessment of relative risk of chronic disease among biological relatives of affected individuals. J Chronic Dis 1982;35:539-51.
22. Byrne C, Brinton LA, Haile RW, et al. Heterogeneity of the effect of family history on breast cancer risk. Epidemiology 1991;2:276-84.
23. Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990;131:961-72.
24. Schildkraut JM, Risch N, Thompson WD. Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. Am J Hum Genet 1989;45:521-9.
25. Jishi MF, Itnyre JH, Oakley-Girvan IA, et al. Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1995;76:1416-21.
26. Goldgar DE, Easton DF, Cannon-Albright LA, et al. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86:1600-8.
27. Schildkraut JM, Thompson WD. Relationship of epithelial ovarian cancer to other malignancies within families. Genet Epidemiol 1988;5:355-67.
28. Anderson DE. Genetic study of breast cancer: identification of a high risk group. Cancer 1974;34:1090-7.
29. Lynch HT, Guirgis HA, Albert S, et al. Familial association of carcinoma of the breast and ovary. Surg Gynecol Obstet 1974;138:717-24.
30. Bailey-Wilson JE, Cannon LA, King MC. Genetic analysis of human breast cancer: a synthesis of contributions to GAW IV. Genet Epidemiol 1986;Suppl 1:15-35.
31. Iselius L, Littler M, Morton N. Transmission of breast cancer - a controversy resolved. Clin Genet 1992;41: 211-17.
32. Newman B, Austin MA, Lee M, et al. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A 1988;85: 3044-8.
33. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study. Am J Hum Genet 1991;48:232-42.
34. Iselius L, Slack J, Littler M, et al. Genetic epidemiology of breast cancer in Britain. Ann Hum Genet 1991;55:151-9.
35. Go RCP, King MC, Bailey-Wilson J, et al. Genetic epidemiology of breast cancer and associated cancers in high-risk families. I. Segregation analysis. J Natl Cancer Inst 1983;71:455-61.
36. Amos CI, Goldstein AM, Harris EL. Familiality of breast cancer and socioeconomic status in blacks. Cancer Res 1991; 51:1793-7.
37. Goldstein AM, Haile RWC, Marazita ML, et al. A genetic epidemiologic investigation of breast cancer in families with bilateral breast cancer. I. Segregation analysis. J Natl Cancer Inst 1987;78:911-18.
38. Chen PL, Sellers TA, Rich SS, et al. Segregation analysis of breast cancer in a population-based sample of postmenopausal probands: the Iowa Women's Health Study. Genet Epidemiol 1995;12:401-15.
39. Hall JM, Lee MK, Newman B, et al. Linkage of early onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-9.
40. Narod SA, Feunteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991;338:82-3.
41. Steichen-Gersdorf E, Gallion HH, Ford D, et al. Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet 1994;55:870-5.
42. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52:678-701.
43. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
44. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
45. Miki Y, Swenson J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
46. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2.
47. Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymp-tomatic testing and screening. JAMA 1995;273:535-41.
48. Friend S, Borresen AL, Brody L, et al. Breast cancer information on the web. (Letter). Nat Genet 1995;11:238-9.
49. Friedman LS, Szabo CI, Ostermeyer EA, et al. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995;57:1284-97.
50. Neuhausen SL, Mazoyer S, Friedman L, et al. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 1996;58:271-80.
51. Stratton MR. Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet 1996;5: 1515-19.
52. Szabo CI, King MC. Inherited breast and ovarian cancer. Hum Mol Genet 1995;4:1811-17.
53. Kinzler KW, Vogelstein B. Breast cancer: what's mice got to do with it? (News). Nature 1996;382:672.
54. FitzGerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996;334:143-9.
55. Langston AA, Malone KE, Thompson JD, et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996;334:137-42.
56. Hopper JL, Giles GG, McCredie MRE, et al. Background, rationale and protocol for a case-control family study of breast cancer. Breast 1994;3:79-86.
57. Newman B, Moorman PG, Millikan R, et al. The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat 1995; 35:51-60.
58. Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997; 336:1125-30.
59. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
60. Offit K, Gilewski T, McGuire P, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996;347:1643-5.
61. Muto MG, Cramer DW, Tangir J, et al. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 1996;56:1250-2.
62. Berman DB, Wagner-Costalas J, Schultz DC, et al. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet 1996;58:1166-76.
63. Johannsson O, Ostermeyer EA, Hakansson S, et al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet 1996;58:441-50.
64. Struewing JP, Brody LC, Erdos MR, et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995;57:1-7.
65. Langsten AA, Stanford JL, Wicklund KG, et al. Germ-line BRCA1 mutations in selected men with prostate cancer. (Letter). Am J Hum Genet 1996;58:881-4.
66. Ingles SA. Logistic random effects models. Doctoral dissertation. Los Angeles, CA: University of California, Los Angeles, 1993.
67. Narod SA, Goldgar D, Cannon-Albright L, et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 1995;64: 394-8.
68. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-90.
69. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378: 789-92.
70. Thorlacius S, Olafsdottir G, Tryggvadottir L, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996;13:117-19.
71. Rebbeck TR, Couch FJ, Kant J, et al. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet 1996;59:547-53.
72. Phelan CM, Lancaster JM, Tonin P, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast-cancer families. Nat Genet 1996;13:120-2.
73. Narod S, Ford D, Devilee P, et al. Genetic heterogeneity of breast-ovarian cancer revisited. (Letter). Am J Hum Genet 1995;57:957-8.
74. Lancaster JM, Wooster R, Mangion J, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996; 13:238-40.
75. Miki Y, Katagiri T, Kasumi F, et al. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 1996;13: 245-7.
76. Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996;13:123-5.
77. Gudmundsson J, Johannesdottir G, Arason A, et al. Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet 1996;58:749-56.
78. Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3663-5.
79. Neuhausen S, Gilewski T, Norton L, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126-8.
80. Zuppan P, Hall JM, Lee MK, et al. Possible linkage of the estrogen receptor gene to breast cancer in a family with late-onset disease. Am J Hum Genet 1991;48:1065-8.
81. Andersen TI, Heimdal KR, Skrede M, et al. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 1994;94:665-70.
82. Wooster R, Mangion J, Eeles R, et al. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 1992;2:132-4.
83. Lobaccaro JM, Lumbroso S, Belon C, et al. Male breast cancer and the androgen receptor gene. (Letter). Nat Genet 1993;5:109-10.
84. Nelen MR, Padberg GW, Peeters EAJ, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996;13:114-16.
85. Malkin D, Li FP, Strong LC, et al. Germ Line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
86. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-304.
87. Frebourg T, Barbier N, Yan YX, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995;56:608-15.
88. Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. Cancer Res 1992;52: 2984-6.
89. Easton DF. Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994;66(6 suppl):S177-82.
90. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 1986;77:89-92.
91. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991;325:1831-6.
92. Swift M, Morrell D, Cromartie E, et al. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 1986;39:573-83.
93. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-53.
94. Krontiris TG, Devlin B, Karp DD, et al. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 1993;329:517-23.
95. Krontiris TG. Minisatellites and human disease. Science 1995;269:1682-3.
96. Garrett PA, Hulka BS, Kim YL, et al. HRAS protooncogene polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev 1993;2:131-8.
97. Phelan CM, Rebbeck TR, Weber BL, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 1996; 12:309-11.
98. Smith G, Stanley L, Sim E, et al. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 1995;25:27-65.
99. Idle JR. Is environmental carcinogenesis modulated by host polymorphism? Mutat Res 1991;247:259-66.
100. Eldridge SR, Gould MN, Butterworth BE. Genotoxicity of environmental agents in human mammary epithelial cells. Cancer Res 1992;52:5617-21.
101. Sadrieh N, Davis CD, Snyderwine EG. N-acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Cancer Res 1996;56:2683-7.
102. Forrester LM, Hayes JD, Millis R, et al. Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis 11: 2163-70, 1990.
103. D'Errico A, Taioli E, Chen S, et al. Genetic polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1996;1:149-73.
104. Palmer JR, Rosenberg L. Cigarette smoking and the risk of breast cancer. Epidemiol Rev 1993;15:145-56.
105. Ambrosone CB, Freudenheim JL, Graham S, et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995;55:3483-5.
106. Ambrosone CB, Freudenheim JL, Graham S, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 1996;276:1494-501.
107. Hunter D, Hankinson S, Hough H, et al. A prospective study of acetylation genotype, cigarette smoking, and risk of breast cancer. (Abstract). Am J Epidemiol 1996;154(suppl):S60.
108. Nebert DW. Elevated estrogen 16 alpha-hydroxylase activity: is this a genotoxic or nongenotoxic biomarker in human breast cancer risk? (Editorial). J Natl Cancer Inst 1993;85:1888-91.
109. Feigelson HS, Coetzee GA, Kolonel LN, et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997;57:1063-5.
110. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41.
111. Jones KA, Brown MA, Solomon E. Molecular genetics of sporadic and familial breast cancer. Cancer Surv 1995;25: 315-34.
112. Porter-Jordan K, Lippman ME. Overview of the biologic markers of breast cancer. Hematol Oncol Clin North Am 1994;8:73-100.
113. Teneriello MG, Park RC. Early detection of ovarian cancer. CA Cancer J Clin 1995;45:71-87.
114. Liu E, Nuzum C. Molecular sleuthing: tracking ovarian cancer progression. (Editorial). J Natl Cancer Inst 1995;87: 1099-101.
115. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993;85:1206-19.
116. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329: 1550-9.
117. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330: 1260-6.
118. Elledge RM, Gray R, Mansour E, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995;87:1254-6.
119. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-16.
120. Kohler MF, Marks JR, Wiseman RW, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993;85:1513-19.
121. Biggs PJ, Warren W, Venitt S, et al. Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unraveling the etiology of cancer. Mutagenesis 1993;8:275-83.
122. Olsson H, Borg A, Ferno M, et al. Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. J Natl Cancer Inst 1991;83:1483-7.
123. Treurniet HF, Rookus MA, Peterse HL, et al. Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor. Cancer Res 1992;52:2344-5.
124. Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77:2318-24.
125. Weiss NS, Liff JM. Accounting for the multicausal nature of disease in the design and analysis of epidemiologic studies. Am J Epidemiol 1983;117:14-18.
126. Millikan R, Dressier L, Geradts J, et al. The need for epidemiologic studies of in-situ carcinoma of the breastz Breast Cancer Res Treat 1995;35:65-77.
127. Khoury MJ, Beaty TH. Applications of the case-control method in genetic epidemiology. Epidemiol Rev 1994;16: 134-50.
128. Hubbard R, Wald E. Exploding the gene myth: how genetic information is produced and manipulated by scientists, physicians, employers, insurance companies, educators, and law enforcers. Boston, MA: Beacon Press, 1993.